BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 32683457)

  • 1. Drug-drug interactions of newly approved small molecule inhibitors for acute myeloid leukemia.
    Megías-Vericat JE; Solana-Altabella A; Ballesta-López O; Martínez-Cuadrón D; Montesinos P
    Ann Hematol; 2020 Sep; 99(9):1989-2007. PubMed ID: 32683457
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New drugs approved for acute myeloid leukaemia in 2018.
    Kucukyurt S; Eskazan AE
    Br J Clin Pharmacol; 2019 Dec; 85(12):2689-2693. PubMed ID: 31469910
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of drug-drug interactions between midostaurin and strong CYP3A4 inhibitors in patients with FLT-3-mutated acute myeloid leukemia (AML).
    Sechaud R; Sinclair K; Grosch K; Ouatas T; Pathak D
    Cancer Chemother Pharmacol; 2022 Jul; 90(1):19-27. PubMed ID: 35751657
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glasdegib for the treatment of acute myeloid leukemia.
    Bruzzese A; Martino EA; Labanca C; Mendicino F; Lucia E; Olivito V; Fimognari F; Neri A; Morabito F; Vigna E; Gentile M
    Expert Opin Pharmacother; 2023; 24(14):1537-1543. PubMed ID: 37392098
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Venetoclax-based therapies for acute myeloid leukemia.
    Guerra VA; DiNardo C; Konopleva M
    Best Pract Res Clin Haematol; 2019 Jun; 32(2):145-153. PubMed ID: 31203996
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent drug approvals for newly diagnosed acute myeloid leukemia: gifts or a Trojan horse?
    Estey E; Karp JE; Emadi A; Othus M; Gale RP
    Leukemia; 2020 Mar; 34(3):671-681. PubMed ID: 31915366
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population pharmacokinetic and exposure-response analyses of ivosidenib in patients with IDH1-mutant advanced hematologic malignancies.
    Jiang X; Wada R; Poland B; Kleijn HJ; Fan B; Liu G; Liu H; Kapsalis S; Yang H; Le K
    Clin Transl Sci; 2021 May; 14(3):942-953. PubMed ID: 33493392
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Isavuconazole therapy in an FLT3 mutated acute myeloid leukemia patient receiving midostaurin: A case report.
    Tollkuci E
    J Oncol Pharm Pract; 2019 Jun; 25(4):987-989. PubMed ID: 29558838
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [European approvals: Glasdegib for Acute myeloid leukemia].
    Barrière S; Gastaud L
    Bull Cancer; 2020 Dec; 107(12):1206-1207. PubMed ID: 33070952
    [No Abstract]   [Full Text] [Related]  

  • 10. Will new agents impact survival in AML?
    Rowe JM
    Best Pract Res Clin Haematol; 2019 Dec; 32(4):101094. PubMed ID: 31779986
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PBPK modeling to predict drug-drug interactions of ivosidenib as a perpetrator in cancer patients and qualification of the Simcyp platform for CYP3A4 induction.
    Bolleddula J; Ke A; Yang H; Prakash C
    CPT Pharmacometrics Syst Pharmacol; 2021 Jun; 10(6):577-588. PubMed ID: 33822485
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How I treat acute myeloid leukemia in the era of new drugs.
    DiNardo CD; Wei AH
    Blood; 2020 Jan; 135(2):85-96. PubMed ID: 31765470
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [New therapeutic agents for acute myeloid leukemia].
    Hosono N
    Rinsho Ketsueki; 2019; 60(9):1108-1119. PubMed ID: 31597834
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of ritonavir dose and schedule on CYP3A inhibition and venetoclax clinical pharmacokinetics.
    Freise KJ; Hu B; Salem AH
    Eur J Clin Pharmacol; 2018 Apr; 74(4):413-421. PubMed ID: 29302721
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of FLT3 and IDH1/2 inhibitors in patients with acute myeloid leukemia previously treated with venetoclax.
    Bewersdorf JP; Shallis RM; Derkach A; Goldberg AD; Stein A; Stein EM; Marcucci G; Zeidan AM; Shimony S; DeAngelo DJ; Stone RM; Aldoss I; Ball BJ; Stahl M
    Leuk Res; 2022 Nov; 122():106942. PubMed ID: 36108424
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [What is recommended in the treatment of acute myeloid leukemia?].
    Thol F
    Internist (Berl); 2019 Dec; 60(12):1240-1250. PubMed ID: 31690995
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantitative Prediction of the Effect of CYP3A Inhibitors and Inducers on Venetoclax Pharmacokinetics Using a Physiologically Based Pharmacokinetic Model.
    Freise KJ; Shebley M; Salem AH
    J Clin Pharmacol; 2017 Jun; 57(6):796-804. PubMed ID: 28052338
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antifungal prophylaxis and novel drugs in acute myeloid leukemia: the midostaurin and posaconazole dilemma.
    Stemler J; Koehler P; Maurer C; Müller C; Cornely OA
    Ann Hematol; 2020 Jul; 99(7):1429-1440. PubMed ID: 32514626
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FDA Approval Summary: Glasdegib for Newly Diagnosed Acute Myeloid Leukemia.
    Norsworthy KJ; By K; Subramaniam S; Zhuang L; Del Valle PL; Przepiorka D; Shen YL; Sheth CM; Liu C; Leong R; Goldberg KB; Farrell AT; Pazdur R
    Clin Cancer Res; 2019 Oct; 25(20):6021-6025. PubMed ID: 31064779
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New drugs creating new challenges in acute myeloid leukemia.
    Tiong IS; Wei AH
    Genes Chromosomes Cancer; 2019 Dec; 58(12):903-914. PubMed ID: 30861214
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.